Stock PTPI PETROS PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

News Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
0.445 USD +9.10% Intraday chart for Petros Pharmaceuticals +5.95% -68.44%
05-29 Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch CI
05-15 Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA OTC Switch
AQ
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch
CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
MT
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading
MT
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication
MT
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
AQ
Lemonaid Health, Inc. Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals
CI
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
AQ
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health
AQ
Petros, Lemonaid Health Collaborate to Expand Stendra Availability
MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health
CI
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process
MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)
CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status
CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
AQ
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
CI
Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?
PR
Top Premarket Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTPI Stock
  4. News Petros Pharmaceuticals